-
Side effects of statins; effects of cannabis use; antihypertensives and lip cancer; and FDA actions.
-
Preclinical studies provide a rationale for examining a role for sunitinib in the treatment of breast cancer. However, in this large, multicenter trial, the combination of sunitinib with docetaxel did not prolong progression-free or overall survival when compared to docetaxel alone, and it appeared to be less well tolerated. The role for sunitinib remains to be established for the treatment of breast cancer.
-
This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors.
-
-
A 61-year-old small business owner was seen in consultation for advice regarding management of a newly discovered pulmonary mass. Seven years previously, he had a 3.5 cm moderately differentiated adenocarcinoma of the sigmoid colon resected along with four regional nodes, all of which were negative for metastatic involvement.
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
In a small, single-institutional, prospective, randomized, placebo-controlled trial, 14 eligible patients (median age 47 years) with clinical and radiographic evidence of radiation necrosis secondary to prior head-and-neck or CNS irradiation were randomized to receive intravenous saline of bevacizumab at 3-week intervals. Patients were followed with serial MRI scans, neurologic examinations, and formal neuropsychological examinations.
-
In a retrospective review of 267 patients evaluated at M.D. Anderson Cancer Center with apparent early-stage, node-negative breast cancer, 15% were found to harbor "occult" metastases upon more intensive scrutiny of the axillary node specimens. In this series, long-term follow-up indicates that such discovery was not associated with a greater frequency of recurrence or poorer survival.
-
In a large retrospective series, 2051 men with clinically localized prostate cancer received definitive radiation therapy (RT) alone. The rates of aspirin use and statin use were 36% and 34%, respectively. The primary endpoint was IBF (interval to biochemical failure) of < 18 months.
-
By a systematic review of observational (case-control and cohort) studies, data regarding aspirin use and cancer risk were compared to data obtained from randomized clinical trials. In general, there was very good correlation regarding reduced risk for several types of cancer and the development of metastatic disease. The analysis provides confidence that observational studies can be of value in addressing the many outstanding questions regarding aspirin and cancer prevention.
